NeuroThera Labs Announces C$5,000,000 Private Placement of Units

About this update from Neurothera Labs Inc.

NeuroThera Labs Announces C$5,000,000 Private Placement of Units (TheNewswire)   Toronto, ON – TheNewswire - June 30, 2026 – NeuroThera Labs Inc. (the “Company” or “NeuroThera”) (TSXV: NTLX) a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it will be proceeding with a non-brokered private placement of up to 37,050,000 units (the "Offered Units") at a price of C$0.135 per Offered Unit for gross proceeds of up to approximately C$5,000,000 (the "Offering").   Each Offered Unit will be comprised of one (1) common share in the capital of the Company (each, a “Unit Share”) and one (1) transferable common share purchase warrant (each, a “Unit Warrant”) entitling the holder thereof to acquire one common share in the capital of the Company (each, a “Unit Warrant Share”) at a price of C$0.18 per Unit Warrant Share for a period of 24 months from the date of issuance thereof.  The Unit Warrants will also have an acceleration provision whereby upon the approval of securities of NeuroThera for trading on the Nasdaq Stock Market, NeuroThera will accelerate the expiry date of 50% of the unexercised Unit Warrants.   Certain insiders of the Company may acquire Offered Units in the Offering. Any participation by insiders in the Offering would constitute a "related party transaction" as defined under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"). However, the Company expects such participation would be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101 as neither the fair market value of the Offered Units subscribed for by the insiders, nor the consideration for the Offered Units paid by such insiders, would exceed 25% of the Company's market capitalization.   The Company intends to use the net proceeds of the Offering for general working capital purposes, including the evaluation of prospective transactions, settlement of liabilities, including repayment of outstanding indebtedness owed to SciSparc Ltd. and other corporate and administrative expenses.   The Unit Shares and Unit Warrants issued under the Offering will be subject to a statutory hold period expiring four months and one ...

View stock analysis, news, and events for Neurothera Labs Inc.